This note is a follow-up to the previous Merlintrader deep dive on Fulcrum Therapeutics (link to the earlier report). Since then, Fulcrum has reshaped its story around pociredir, an oral HbF inducer for sickle cell disease (SCD), delivered a series of positive PIONEER data updates and, crucially, raised fresh capital to extend runway well beyond the next set of readouts.

As of the afternoon session on 21 January 2026, Altimmune is trading around 4.5–4.6 USD, up roughly 9% versus the prior close. Volumes are clearly above a quiet day but not at “capitulation” or “meme-stock” levels. There is no new 8-K or press release dated today, and the official IR feed has not dropped fresh clinical or corporate news.

From INPEFA reset to pilavapadin, SONATA-HCM, Zynquista and LX9851: a compact roadmap for the next 18–24 months.

The short version: Novavax is no longer just fighting for survival as a COVID single-product story. With Sanofi first and Pfizer now, Matrix-M is slowly turning into a royalty platform. The balance sheet is still tight and the story remains binary, but the “all-or-nothing” risk has shifted a bit more towards “long-duration option on partner execution”.

Fractyl Health is a small-cap metabolic therapeutics company listed on Nasdaq under the ticker GUTS. The company’s core bet is that a one-time endoscopic procedure on the duodenum, combined eventually with gene therapy, can offer a durable “off-ramp” for patients who need or want to come off GLP-1 drugs but would otherwise regain weight quickly.

Corvus Pharmaceuticals is a clinical-stage biotech now almost entirely defined by soquelitinib, an oral, highly selective ITK inhibitor designed to “rebalance” T-cell responses. The drug sits at the intersection of two very different but complementary franchises: inflammatory skin disease (atopic dermatitis) and T-cell lymphomas (PTCL and related entities).

Novocure (NVCR) is one of those oncology names that sit in the grey area between classic “biotech” and medical devices. The company sells wearable Tumor Treating Fields (TTFields) devices (Optune Gio and Optune Lua) for aggressive solid tumors like glioblastoma and metastatic NSCLC, generating several hundred million dollars in annual revenue, but it is still loss-making and heavily exposed to binary regulatory and clinical outcomes.

Atossa Therapeutics is a small-cap, clinical-stage biotech built around a single platform asset, the oral selective estrogen receptor modulator (SERM) (Z)-endoxifen. Until 2025 the investment story was mostly about breast cancer treatment and risk reduction, but in the last few months the company has opened a new front in Duchenne muscular dystrophy (DMD).

The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division.